The view at a glance.

Active shortages skew toward injectables, controlled substances, and drugs with concentrated API sourcing. Several months-long shortages directly affect commercial Part D members; many require plan-side workarounds: prior-auth carveouts, alternative-product coverage, or quantity-limit suspension. Discontinued drugs are not shown here — those have stopped manufacture permanently.